Omeros (OMER) Non-Current Deffered Revenue (2012 - 2018)
Omeros recorded quarterly Non-Current Deffered Revenue of $8.2 million in Q4 2018, down 1.78% quarter-over-quarter from $8.3 million in Q3 2018, and down 6.21% year-over-year from $8.7 million in Q4 2017.
Omeros' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $8.2 million for Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 6.21% year-over-year to $8.2 million; the TTM figure through Dec 2018 stood at $8.2 million (down 6.21% YoY), while the FY2018 annual figure was $8.2 million, down 6.21% from the prior year.
- Non-Current Deffered Revenue came in at $8.2 million for Q4 2018 at Omeros, down from $8.3 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $9.2 million in Q1 2016 to a low of $8.2 million in Q4 2018.
- A 5-year average of $8.9 million and a median of $9.0 million in 2017 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue surged 122.99% in 2014 and decreased 6.21% in 2018, its largest moves.
- Omeros' Non-Current Deffered Revenue stood at $9.0 million in 2014, then advanced by 1.73% to $9.2 million in 2015, then fell by 0.71% to $9.1 million in 2016, then decreased by 4.64% to $8.7 million in 2017, then fell by 6.21% to $8.2 million in 2018.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $8.2 million, $8.3 million, and $8.5 million for Q4 2018, Q3 2018, and Q2 2018 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 8.18 Mn |
| Sep 30, 2018 | 8.33 Mn |
| Jun 30, 2018 | 8.45 Mn |
| Mar 31, 2018 | 8.58 Mn |
| Dec 31, 2017 | 8.72 Mn |
| Sep 30, 2017 | 8.84 Mn |
| Jun 30, 2017 | 8.94 Mn |
| Mar 31, 2017 | 9.04 Mn |
| Dec 31, 2016 | 9.14 Mn |
| Sep 30, 2016 | 9.19 Mn |
| Jun 30, 2016 | 9.21 Mn |
| Mar 31, 2016 | 9.22 Mn |
| Dec 31, 2015 | 9.21 Mn |
| Sep 30, 2015 | 9.17 Mn |
| Jun 30, 2015 | 9.13 Mn |
| Mar 31, 2015 | 9.09 Mn |
| Dec 31, 2014 | 9.05 Mn |
| Sep 30, 2014 | 8.94 Mn |
| Jun 30, 2014 | 8.67 Mn |
| Mar 31, 2014 | 8.41 Mn |
| Dec 31, 2013 | 8.15 Mn |
| Sep 30, 2013 | 7.63 Mn |
| Jun 30, 2013 | 6.61 Mn |
| Mar 31, 2013 | 3.77 Mn |
| Dec 31, 2012 | 4.64 Mn |
| Sep 30, 2012 | 3.09 Mn |
| Jun 30, 2012 | 3.01 Mn |
| Mar 31, 2012 | 3.06 Mn |